DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME

用于左心发育不全综合征的肺流量限制器的开发

• 批准号: 10383607
• 负责人: Beverly Tang
• 金额: $ 44.8万
• 依托单位: STARLIGHT CARDIOVASCULAR, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-02-15 至 2023-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10383607
• 关键词: Address; American; Anatomic Models; Anatomy; Animal Testing; Animals; Biomechanics; Birth; Blood Circulation; Blood flow; Boston; Brain; Cardiopulmonary Bypass; Cardiovascular system; Catheters; Chest; Childhood; Clinical; Clinical Research; Clinical Trials; Computer Models; Congenital Heart Defects; Device Designs; Device or Instrument Development; Devices; Distal; Ductus Arteriosus; Environment; Evaluation; FDA approved; Femoral vein; Future; Grant; Growth; Hospital Costs; Hybrids; Hypoplastic Left Heart Syndrome; Implant; Intervention; Left; Left ventricular structure; Length; Length of Stay; Life; Liquid substance; Lung; Mechanics; Medical Device; Modeling; Morbidity - disease rate; Newborn Infant; Operative Surgical Procedures; Oxygen; Patient-Focused Outcomes; Patients; Pediatric Hospitals; Phase; Procedures; Pulmonary Artery Branch; Pulmonary artery structure; Reconstructive Surgical Procedures; Research Design; Risk; Safety; Small Business Innovation Research Grant; Stents; Surgical sutures; System; Testing; Thinness; Thrombosis; Universities; Venous; Work; artery stenosis; base; clinically relevant; commercialization; cost; design; hemodynamics; implant design; improved; in silico; in vivo; innovation; lung pressure; model development; mortality; neonate; palliation; prevent; prototype; pulmonary arterial pressure; reconstruction; verification and validation

ABSTRACT Starlight Cardiovascular is developing what will be the first FDA approved percutaneous flow restrictor to replace surgical banding in congenital heart defects (CHD), including Hypoplastic Left Heart Syndrome (HLHS). The potential worldwide market for the Starlight Flow Restrictor is over $200M. Approximately 1,000 Americans are born each year with Hypoplastic Left Heart Syndrome (HLHS), a condition where the left ventricle is severely underdeveloped or barely present. Babies born with HLHS require palliation surgery, commonly a Norwood procedure, within days after birth to survive, subjecting the neonate to cardiopulmonary bypass and a costly, invasive surgery. A hybrid (half surgical and half percutaneous) palliation procedure exists as an alternative, however a limitation of the hybrid procedure is reliable branch pulmonary artery banding. Branch pulmonary artery banding requires an open surgery and can interfere with pulmonary artery growth, necessitating pulmonary artery reconstruction surgery. Attempts at modifying existing devices to create percutaneous flow restrictors to replace surgical banding produced some promising clinical results. However use of these modified devices is limited by technical challenges such as large and stiff delivery systems, long implant lengths, lack of adjustability and reliability, and designs that increase thrombosis risk. Starlight Cardiovascular is developing a percutaneous and adjustable branch pulmonary artery blood flow restrictor to replace surgical banding. Our device addresses the shortcomings from previous attempts at a percutaneous flow restrictor, by providing safe venous implant delivery, reliable flow reduction, percutaneous adjustability, beneficial hemodynamics, and a short and well anchored implant design that is removable. These pulmonary flow restrictors designed for HLHS can be modified to also replace main pulmonary artery banding, more than doubling the number of patients who could benefit. This Phase I SBIR grant will consist of computational fluid dynamics modeling and testing to inform device design, benchtop model development, and final device design selection through end-user benchtop testing by pediatric interventional cardiologists. Successful completion of this project will produce a final device design that is ready for animal testing, design refinement, and Verification and Validation testing in Phase II, which will prepare the flow restrictor device for a clinical trial, FDA Humanitarian Device Exemption approval, and commercialization.

摘要